2021年健康元药业集团股份有限公司三季报

证券代码：600380 证券简称：健康元 健康元药业集团股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中 财务报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 本季度报告分别以中文及英文编订，如对中英文文本的理解发生歧义时，概以中文文本 为准。 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 本报告期比上年同 年初至报告期末比上年 项目 本报告期 期增减变动幅度 年初至报告期末 同期增减变动幅度(%) (%) 营业收入 4,098,276,714.19 12.98 11,933,648,988.85 18.12 归属于上市公司股东的净利润 321,327,690.20 27.91 1,008,675,184.73 8.76 归属于上市公司股东的扣除非经 常性损益的净利润 321,676,905.90 52.36 919,569,233.33 14.45 经营活动产生的现金流量净额 不适用 不适用 1,621,169,704.58 -18.31 基本每股收益（元/股） 0.1640 25.67 0.5154 7.64 稀释每股收益（元/股） 0.1638 26.49 0.5142 7.96 加权平均净资产收益率（%） 2.85 增加 0.47 个百分点 8.89 增加 0.17 个百分点 本报告期末 上年度末 本报告期末比上年度末 增减变动幅度(%) 总资产 29,154,637,491.82 28,156,977,599.07 3.54 归属于上市公司股东的所有者权 益 11,314,080,616.51 11,096,125,890.51 1.96 注：1、“本报告期”指本季度初至本季度末 3 个月期间，下同。 2、2021 年 1-9 月，本公司实现营业收入 119.34 亿元，同比增长 18.12%，主要系化学制剂重 点专科领域品种销量显著增长所致。前三季度，化学制剂实现收入 69.07 亿元，同比增长 40.96%， 其中，呼吸制剂产品实现收入 2.74 亿元，同比增长 957.88%；抗感染产品实现收入 10.53 亿元， 同比下降 0.19%；消化道产品实现收入 29.93 亿元，同比增长 68.66%；促性激素产品实现收入 19.78 亿元，同比增长 37.75%；精神产品实现收入 3.06 亿元，同比增长 49.77%。原料药及中间体实现 收入 34.41 亿元，同比增长 17.51%。中药制剂实现收入 8.53 亿元，同比下降 10.53%。诊断试剂 及设备实现收入 5.52 亿元，同比下降 52.64%。保健品实现收入 0.86 亿元，同比下降 20.28%。 (二)非经常性损益项目和金额 单位：元 币种：人民币 项目 本报告期金额 年初至报告期末金额 说明 非流动性资产处置损益（包括已计 固定资产处置收益 提资产减值准备的冲销部分） 528,115.38 20,878,916.52 计入当期损益的政府补助（与公司 正常经营业务密切相关，符合国家 计入当期损益的政府补助 政策规定、按照一定标准定额或定 45,995,421.31 175,456,418.58 量持续享受的政府补助除外） 除同公司正常经营业务相关的有效 套期保值业务外，持有交易性金融 交易性金融资产/负债的公 资产、交易性金融负债产生的公允 允价值变动损益，以及持有 价值变动损益，以及处置交易性金 -48,806,320.50 6,742,628.05 和处置交易性金融资产/负 融资产、交易性金融负债和可供出 债取得的投资收益 售金融资产取得的投资收益 除上述各项之外的其他营业外收入 除上述各项之外的其他营业 和支出 -12,046,187.71 -13,444,794.44 外收入和支出 减：所得税影响额 3,376,118.90 29,574,335.32 上述项目所得税的影响额 少数股东权益影响额（税后） 上述项目少数股东应享有的 -17,355,874.72 70,952,881.99 部分 合计 -349,215.70 89,105,951.40 将《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益 项目界定为经常性损益项目的情况说明 □适用 √不适用 (三)主要会计数据、财务指标发生变动的情况、原因 √适用 □不适用 项目名称 变动比例（%） 主要原因 归属于上市公司股东的扣除非经常性损益 主要系本报告期化学制剂产品销售收入取得 的净利润_本报告期 52.36 显著增长，带动净利润实现高增长。 (四)其他会计报表项目、财务指标重大变动的情况及原因 单位：元 币种：人民币 资产负债表 2021 年 9 月 30日 2020 年 12 月 31 日 变动比例 主要原因 （%） 主要系子公司丽珠集团持有的 SCC VENTURE VII 交易性金融资产 189,909,950.41 28,328,748.72 570.38 2018-C,L.P.已注销，收到分配的其原持有的 Beam Therapeutics Inc.（NASDAQ：BEAM）股票所致。 预付款项 522,396,275.49 209,926,040.57 148.85 主要系本期预付材料采购款及费用增加所致。 一年内到期的非流 8,634,022.41 19,934,376.07 -56.69 主要系子公司丽珠集团本期收回转让控股子公司部分 动资产 股权的对价款所致。 长期股权投资 1,418,022,709.96 628,279,599.73 125.70 主要系子公司丽珠集团受让天津Joincare Pharmaceutical Group Industry Co., Ltd. 2021 Third Quarterly Report 1 / 18 Stock code：600380 Stock abbreviation：健康元 Joincare Pharmaceutical Group Industry Co., Ltd. 2021 Third Quarterly Report Board of Directors (the “Board”) and all directors of the Company hereby warrant that there are no false representations, misleading statements or material omissions contained in the third quarterly report (the “Report”), and severally and jointly accept responsibility for the truthfulness, accuracy and completeness of the contents of the Report. IMPORTANT NOTICE: The Board, the Supervisory Committee and the directors, supervisors and senior management of the Company hereby warrant the truthfulness, accuracy and completeness of the contents of the Report, and that there are no false representations, misleading statements or material omissions contained in the Report, and severally and jointly accept responsibility. The person-in-charge of the Company, the person-in-charge of the Company's accounting work and the person-in-charge of the accounting department (the head of the accounting department) hereby warrant the truthfulness, accuracy and completeness of the financial statements contained in the Report. Whether the third quarterly financial statements are audited □Applicable √N/A The Report is prepared in both Chinese and English. In case of any ambiguity in the understanding of the Chinese and English texts, the Chinese version shall prevail. Joincare Pharmaceutical Group Industry Co., Ltd. 2021 Third Quarterly Report 2 / 18 I Principal Financial Data (I) Principal accounting data and financial indicators Unit: Yuan Currency: RMB Item The Reporting Period (July-September 2021) Year-on-Year Change (%) From the beginning of the year to the end of the Reporting Period (January – September 2021) Year-on-Year Change (%) Revenues 4,098,276,714.19 12.98 11,933,648,988.85 18.12 Net profit attributable to Shareholders of the listed company 321,327,690.20 27.91 1,008,675,184.73 8.76 Net profit attributable to Shareholders of the listed company after deducting the extraordinary gain or loss 321,676,905.90 52.36 919,569,233.33 14.45 Net cash flow from operating activities N/A N/A 1,621,169,704.58 -18.31 Basic earnings per share (RMB/share) 0.1640 25.67 0.5154 7.64 Diluted earnings per share (RMB/share) 0.1638 26.49 0.5142 7.96 Weighted average return on net assets (%) 2.85 Increased by 0.47 percentage point 8.89 Increased by 0.17 percentage point End of the Reporting Period End of the Previous Year Change (%) Total assets 29,154,637,491.82 28,156,977,599.07 3.54 Owners’ equity attributable to Shareholders of the listed company 11,314,080,616.51 11,096,125,890.51 1.96 Note: 1. “Reporting Period” refers to the 3rd Quarter of 2021, from July 1, 2021 to September 30, 2021. 2. From January to September 2021, the Company recorded operating revenues of RMB 11,934 million, representing an increase of 18.12% year-on-year; the main driver of the growth is significant increasing sales volume of main product categories in key specialist arenas of the Chemical drug preparation segment. Revenues from chemical drug preparation products amounted to RMB 6,907 million, representing an increase of 40.96% year-on-year, of which, revenues from Inhalation products amounted to 274 million, representing an increase of 957.88% year-on-year; Revenues from anti-infective drugs amounted to RMB1,053 million, representing a decrease of 0.19% year-on-year; Revenues from gastroenterology products amounted to RMB 2,993 million, representing an increase of 68.66% year-on-year; Revenues from gonadotropic hormones products amounted to RMB 1,978 million, representing an increase of 37.75% year-on-year; Revenues from psychiatric products amounted to RMB 306 million, representing an increase of 49.77% year-on-year. Revenues from APIs and intermediates amounted to RMB 3,441 million, representing an increase of 17.51% year-on-year. Revenues from traditional Chinese drug preparation products amounted to RMB 853 million, representing a decrease of 10.53% year-on-year. Revenues from diagnostic reagents and equipment products amounted to RMB552 million, representing a decrease of 52.64% year-on-year. Revenues from health care products amounted to RMB 86 million, representing a decrease of 20.28% year-on-year. Joincare Pharmaceutical Group Industry Co., Ltd. 2021 Third Quarterly Report 3 / 18 (Ⅱ) Items and amounts of extraordinary gains and losses Unit: Yuan Currency: RMB Item Amounts for the Reporting Period Amount from the beginning of the year to the end of the Reporting Period (January – September 2021) Description Gains and losses on disposal of non-current assets (Including the write-off part of the provision for impairment of assets） 528,115.38 20,878,916.52 Proceeds from disposal of fi